AstraZeneca plc diskutieren

Financial performance for Q1 2024 (Growth numbers at CER):

• Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines
• Double-digit growth in Total Revenue from Oncology at 26%, CVRM at 23%, R&I at 17%, and Rare Disease at 16%.
• Core Product Sales Gross Margin3 of 82%
• Core Operating Margin of 34%
• Core Tax Rate of 21%
• Core EPS increased 13% to $2.06. The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights
• Total Revenue and Core EPS guidance at CER for FY 2024 reiterated

.